- Home
- DAWN vs IPXX Comparison
DAWN vs IPXX Comparison
Compare DAWN & IPXX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DAWN
- IPXX
- Stock Information
- Founded
- DAWN 2018
- IPXX 2023
- Country
- DAWN United States
- IPXX United States
- Employees
- DAWN N/A
- IPXX N/A
- Industry
- DAWN Biotechnology: Pharmaceutical Preparations
- IPXX Blank Checks
- Sector
- DAWN Health Care
- IPXX Finance
- Exchange
- DAWN Nasdaq
- IPXX Nasdaq
- Market Cap
- DAWN 1.3B
- IPXX 337.5M
- IPO Year
- DAWN 2021
- IPXX 2023
- Fundamental
- Price
- DAWN $12.79
- IPXX $10.99
- Analyst Decision
- DAWN Strong Buy
- IPXX
- Analyst Count
- DAWN 7
- IPXX 0
- Target Price
- DAWN $36.17
- IPXX N/A
- AVG Volume (30 Days)
- DAWN 937.9K
- IPXX 14.0K
- Earning Date
- DAWN 10-30-2024
- IPXX 01-01-0001
- Dividend Yield
- DAWN N/A
- IPXX N/A
- EPS Growth
- DAWN N/A
- IPXX N/A
- EPS
- DAWN N/A
- IPXX 0.37
- Revenue
- DAWN $101,953,000.00
- IPXX N/A
- Revenue This Year
- DAWN N/A
- IPXX N/A
- Revenue Next Year
- DAWN $36.10
- IPXX N/A
- P/E Ratio
- DAWN N/A
- IPXX $29.44
- Revenue Growth
- DAWN N/A
- IPXX N/A
- 52 Week Low
- DAWN $11.94
- IPXX $10.31
- 52 Week High
- DAWN $18.07
- IPXX $15.18
- Technical
- Relative Strength Index (RSI)
- DAWN 39.97
- IPXX 44.61
- Support Level
- DAWN $12.26
- IPXX $10.76
- Resistance Level
- DAWN $12.81
- IPXX $15.18
- Average True Range (ATR)
- DAWN 0.52
- IPXX 0.86
- MACD
- DAWN -0.05
- IPXX -0.16
- Stochastic Oscillator
- DAWN 28.94
- IPXX 5.23
About DAWN Day One Biopharmaceuticals Inc.
Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The product candidate, DAY101, is an oral, brain-penetrant, highly-selective type II pan-rapidly accelerated fibrosarcoma, or pan-RAF, kinase inhibitor.
About IPXX Inflection Point Acquisition Corp. II
Inflection Point Acquisition Corp II is a blank check company. It is formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses.